Search Result

Results for "

anti-metastatic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibiotic (1) Apoptosis (18) Aurora Kinase (1) Autophagy (5) Bacterial (2) Cathepsin (1) CXCR (1) EGFR (1) Endogenous Metabolite (4) ERK (2) Fluorescent Dye (1) Glucosidase (1) HDAC (3) Integrin (1) JNK (1) Lipoxygenase (1) MMP (6) Monoamine Oxidase (1) mTOR (1) Necroptosis (2) NF-κB (3) PAI-1 (2) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (1) PKC (1) Prostaglandin Receptor (1) Protease Activated Receptor (PAR) (1) Ras (2) ROCK (1) Ser/Thr Protease (1) TGF-β Receptor (3) TrxR (1) Wnt (4)
By Research Areas:	Cancer (61) Cardiovascular Disease (4) Endocrinology (2) Infection (3) Inflammation/Immunology (12) Neurological Disease (6)

By Targets:

Akt (1)

Antibiotic (1)

Apoptosis (18)

Aurora Kinase (1)

Autophagy (5)

Bacterial (2)

Cathepsin (1)

CXCR (1)

EGFR (1)

Endogenous Metabolite (4)

ERK (2)

Fluorescent Dye (1)

Glucosidase (1)

HDAC (3)

Integrin (1)

JNK (1)

Lipoxygenase (1)

MMP (6)

Monoamine Oxidase (1)

mTOR (1)

Necroptosis (2)

NF-κB (3)

PAI-1 (2)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PI3K (1)

PKC (1)

Prostaglandin Receptor (1)

Protease Activated Receptor (PAR) (1)

Ras (2)

ROCK (1)

Ser/Thr Protease (1)

TGF-β Receptor (3)

TrxR (1)

Wnt (4)

By Research Areas:

Cancer (61)

Cardiovascular Disease (4)

Endocrinology (2)

Infection (3)

Inflammation/Immunology (12)

Neurological Disease (6)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146695

S100P-IN-1

Others Cancer

S100P-IN-1 (Compound 4) is a S100P inhibitor with an IC₅₀ of 22.7 nM. S100P-IN-1 shows anti-metastatic effects on pancreatic cancer cells .
HY-N3360

Lupalbigenin

Apoptosis Cancer

Lupalbigenin is a natural compound with anti-metastatic and pro-apoptotic effects .

S100P-IN-1	Others	Cancer
S100P-IN-1 (Compound 4) is a S100P inhibitor with an IC₅₀ of 22.7 nM. S100P-IN-1 shows anti-metastatic effects on pancreatic cancer cells .

Lupalbigenin	Apoptosis	Cancer
Lupalbigenin is a natural compound with anti-metastatic and pro-apoptotic effects .

HY-136718

CLEFMA	Apoptosis	Cancer
CLEFMA is a curcuminoid with antitumor activity. CLEFMA inhibits tumor growth is associated with NF-κB-regulated anti-inflammatory and anti-metastatic effects .

HY-19118

KP1019

FFC14A
Apoptosis Cancer

KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells .

KP1019 FFC14A	Apoptosis	Cancer
KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells .

HY-149412

MHJ-627	ERK	Cancer
MHJ-627 is a potent ERK5 (MAPK7) inhibitor (IC₅₀: 0.91 μM). MHJ-627 promotes the mRNA expression of tumor suppressors and anti-metastatic genes, and promotes cancer cell death .

HY-113462

α-Carotene	Others	Cancer
α-Carotene, a precursor of vitamin A, is used as an anti-metastatic agent or as an adjuvant for anti-cancer agents. α-Carotene is isolated from yellow-orange and dark-green vegetables .

HY-162379

Anticancer agent 200

Others Cancer

Anticancer agent 200 (6d) is a potential noncovalent anticancer inhibitor and an anti-metastatic agent .

Anticancer agent 200	Others	Cancer
Anticancer agent 200 (6d) is a potential noncovalent anticancer inhibitor and an anti-metastatic agent .

HY-147522

ADG-2e	Bacterial Antibiotic	Infection Cancer
ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells .

HY-111578

BDP-13176 1 Publications Verification	Others	Cancer
BDP-13176 is a potent fascin 1 inhibitor, with a K_d of 90 nM and an IC₅₀ of 240 nM. BDP-13176 has potential as an anti-metastatic agent .

HY-124674

CCT365623

Lipoxygenase Cancer

CCT365623 is a potent and orally active LOX inhibitor with an IC₅₀ of 0.9 μM. CCT365623 has potent anti-metastatic efficacy in vivo .

CCT365623	Lipoxygenase	Cancer
CCT365623 is a potent and orally active LOX inhibitor with an IC₅₀ of 0.9 μM. CCT365623 has potent anti-metastatic efficacy in vivo .

HY-107146

PZ-128 P1pal-7	Protease Activated Receptor (PAR)	Cardiovascular Disease Cancer
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1 (PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .

HY-122714

SK-216	PAI-1	Cancer
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma .

HY-16172

DMAPT Dimethylamino Parthenolide	NF-κB	Cancer
DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD₅₀ of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect .

HY-13696

MSX-122 1 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC₅₀ of ∼10 nM. MSX-122 has anti-inflammatory and anti-metastatic activity.

HY-16172A

(S)-DMAPT (S)-Dimethylamino Parthenolide	NF-κB	Cancer
(S)-DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD₅₀ of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect .

HY-118837

WF-536	ROCK	Cancer
WF-536 is an orally active inhibitor of Rho-associated coiled-coil-containing protein kinase (ROCK). WF-536 has tumor anti-metastatic activity. WF-536 can be used for the research of cancer .

HY-146684

HDAC-IN-36	HDAC Autophagy Apoptosis	Cancer
HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC₅₀ of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research .

HY-N2022

Castanospermine 2 Publications Verification	Glucosidase	Inflammation/Immunology Cancer
Castanospermine is a natural alkaloid that can be extracted from black beans or the Moreton Bay chestnut tree (Castanospermum australae). Castanospermine is an α/ β-glucosidase inhibitor. Castanospermine has anti-inflammatory, antiviral replication and anti-metastatic effects on prostate cancer. Castanospermine can be used as an immunosuppressant to prevent transplant rejection .

HY-B0617

S-Adenosyl-L-methionine S-Adenosyl methionine; Ademetionine; AdoMet	Endogenous Metabolite Apoptosis	Neurological Disease Inflammation/Immunology Cancer
S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .

HY-113612A

Cytostatin sodium	Apoptosis Phosphatase	Cancer
Cytostatin sodium is an effective and selective protein phosphatase 2A (PP2A) inhibitor with an IC50 value of 210 nM. Cytostatin sodium exhibits anti-metastatic properties, good antitumor activity, and can induce apoptosis. Cytostatin sodium can also prevent the adhesion of B16 melanoma cells to components of the extracellular matrix (laminin and collagen). Cytostatin sodium belongs to the family of natural product fosriecin .

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-N2587

Irigenin	Integrin Apoptosis	Cancer
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-151802

CPUL1	TrxR	Cancer
CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective .

HY-111172

Inotilone	MMP NF-κB	Cancer
Inotilone is an inhibitor of matrix metalloproteinase MMP-2 and MMP-9, to against metastatic in lung cancer cells. Inotilone enhances the activity of the antioxidant enzymes to support its anti-metastatic activity. Inotilone also inhibits IκBα phosphorylation and NFκB p65 nuclear translocation, involving in FAK, PI3K/AKT, MAPKs and NFκB pathways .

HY-W017770

S-Adenosyl-L-methionine disulfate tosylate 5+ Cited Publications Ademetionine disulfate tosylate; S-Adenosyl methionine disulfate tosylate; AdoMet disulfate tosylate	Endogenous Metabolite Apoptosis	Neurological Disease Cancer
S-Adenosyl-L-methionine disulfate tosylate is the disulfate tosylate form of S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .

HY-16929

Latrunculin A 5+ Cited Publications LAT-A
Latrunculin A (LAT-A), found in the red sea sponge Latrunculia magnifica, is a G-actin polymerization inhibitor. Latrunculin A binds to actin monomers and inhibits polymerization of actin with K_ds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively. Latrunculin A has effective anti-metastatic properties for cancer research. Latrunculin A blocks cell migration .

HY-B0617B

S-Adenosyl-L-methionine (1,4-butanedisulfonate) S-Adenosyl methionine (1,4-butanedisulfonate); Ademetionine (1,4-butanedisulfonate); AdoMet (1,4-butanedisulfonate)	Endogenous Metabolite Apoptosis	Neurological Disease Inflammation/Immunology Cancer
S-Adenosyl-L-methionine (S-Adenosyl methionine) 1,4-butanedisulfonate is an orally active methyl group donor. S-Adenosyl-L-methionine 1,4-butanedisulfonate is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine 1,4-butanedisulfonate also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine 1,4-butanedisulfonate has the potential for, cancer, liver disease and osteoarthritis research .

HY-123976

MPT0G211	HDAC	Neurological Disease Cancer
MPT0G211 is a potent, orally active and selective HDAC6 inhibitor (IC₅₀=0.291 nM). MPT0G211 displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 can penetrate the blood-brain barrier. MPT0G211 ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-123976A

MPT0G211 mesylate	HDAC	Neurological Disease Cancer
MPT0G211 mesylate is a potent, orally active and selective HDAC6 inhibitor (IC₅₀=0.291 nM). MPT0G211 mesylate displays >1000-fold selective for HDAC6 over other HDAC isoforms. MPT0G211 mesylate can penetrate the blood-brain barrier. MPT0G211 mesylate ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. MPT0G211 mesylate has anti-metastatic and neuroprotective effects. Anticancer activities .

HY-N0187

4-Methylumbelliferone 2 Publications Verification Hymecromone; 4-MU	Others	Cardiovascular Disease Cancer
4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.

HY-116107

AG311

Necroptosis Cancer

AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .

AG311	Necroptosis	Cancer
AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .

HY-121076

Berteroin	Bacterial	Infection Inflammation/Immunology Cancer
Berteroin, a naturally occurring Sulforaphane analog, ia an antimetastatic agent. Berteroin has anti-inflammatory, antitumor and bactericidal effects .

HY-N1376

(20R)-Ginsenoside Rg3 2 Publications Verification (20R)-Propanaxadiol; R-ginsenoside Rg3	Others	Cancer
(20R)-ginsenoside Rg3 ((20R)-Propanaxadiol), one of the active compounds present in ginseng root, inhibits angiogenesis, and has anti-carcinogenic and antimetastatic effects .

HY-N12601

Diselaginellin B	Apoptosis	Cancer
Diselaginellin B (compound 2) is a natural product isolated from Selaginella Pulvinata, which exhibits anti-proliferative, apoptosis-inducing and antimetastatic activities against human carcinoma hepatocellular cells .

HY-163290

HDAC-MB	Fluorescent Dye Monoamine Oxidase	Cancer
HDAC-MB a probe that is activated by HDAC6 and can detect and eliminate glioma cells through activation by HDAC6. HDAC-MB reveals antimetastatic and antiproliferative properties, inhibits glioma invasion and induces cellular apoptosis .

HY-N6036

Ganoderic acid F 1 Publications Verification	Others	Cancer
Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress .

HY-N0579

Fraxin 2 Publications Verification Fraxoside	Phosphodiesterase (PDE)	Inflammation/Immunology
Fraxin isolated from Cortex Fraxini, is a glucoside of fraxetin and reported to exert potent anti-oxidative stress action , anti-inflammatory and antimetastatic properties. Fraxin shows its antioxidative effect through inhibition of cyclo AMP phosphodiesterase enzyme .

HY-123071

Box5	Wnt	Cancer
Box5 is a potent Wnt5a antagonist. Box5 inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca ²⁺ release. Box5 inhibits cell migration. Box5 has the potential for the research of melanoma .

HY-123071A

Box5 TFA 2 Publications Verification	Wnt	Cancer
Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca ²⁺ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma .

HY-103070

PythiDC	MMP	Inflammation/Immunology
PythiDC is a selective collagen prolyl 4-hydroxylase (CP4H1) inhibitor with an IC₅₀ value of 4.0 μM. PythiDC can be used as a CP4H probe and also can be used for the development of a new class of antifibrotic and antimetastatic agents .

HY-P2970

Stem bromelain	Apoptosis	Inflammation/Immunology Cancer
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .

HY-19928

Vactosertib 3 Publications Verification EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-100415

UKI-1 WX-UK1; UKI-1C	PAI-1 Ser/Thr Protease	Cancer
UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a K_i of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells .

HY-19928A

Vactosertib Hydrochloride 3 Publications Verification EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-152204

Cathepsin L/S-IN-1	Cathepsin	Cancer
Cathepsin L/S-IN-1 is a dual inhibitor of Cathepsin L and Cathepsin S with IC₅₀s of 4.10 μM and 1.79 μM, respectively. Cathepsin L/S-IN-1 shows a significant antimetastatic and invasive effects on pancreatic cancer BxPC-3 and PANC-1 cells .

HY-131417

cis-ACCP	MMP	Infection Cardiovascular Disease Inflammation/Immunology Cancer
cis-ACCP is an orally active antimetastatic matrix metalloproteinase-2 (MMP-2) selective inhibitor. cis-ACCP can inhibit MMP-2 and MMP-9 with IC₅₀ values of 4 μM and 20 μM, respectively. cis-ACCP can be used for the research of a variety of chronic diseases .

HY-149344

Anticancer agent 133	Apoptosis Autophagy EGFR	Cancer
Anticancer agent 133 (compound Rh2) is an anti-cancer agent with cytotoxic and antimetastatic activities. Anticancer agent 133 induces cell cycle arrest, apoptosis, and autophagy. Anticancer agent 133 also inhibits cell metastasis via suppression of EGFR expression mediated by FAK-regulated integrin β1 .

HY-118032

Bozepinib	Apoptosis Autophagy JNK ERK	Cancer
Bozepinib is a PKR (RNA-dependent protein kinase) activator and potently inhibits the HER-2 signaling pathway as well as JNK and ERK kinases. Bozepinib induces PKR-mediated apoptosis and synergizes with IFNα to trigger apoptosis, autophagy and senescence. Bozepinib also demonstrates in vivo antitumor and antimetastatic efficacy in xenografted nude mice .

HY-102078

ZINC69391 1 Publications Verification	Ras Apoptosis	Cancer
ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects .

HY-P1416

Foxy-5	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

Cat. No.	Product Name	Target	Research Area

HY-P0122B

iRGD peptide 1 TFA	Peptides	Cancer
iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers agents deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity .